

Curriculum Vitae
Dott.ssa Roberta Lucianò

PERSONAL INFORMATION

Name: Roberta

Surname: Lucianò

Address: Milan, Italy

Telephone: +39 --

E-mail: luciano.roberta@hsr.it -

Nationality: Italian

Date of Birth: 15/02/1978

WORK EXPERIENCES

Jan 2017 – present **Full staff Pathologist**

San Raffaele Hospital– Via Olgettina 60 – 20132 Milan*

Pathology Department (Chief: Prof. C. Doglioni)

Grossing and processing of surgical specimens. Preparation of paraffin embedded tissue, as well as intraoperative frozen sections. Assessment of H&E-stained, and immunohistochemistry (IHC) specimens. Expertise in molecular pathology techniques.

**Part of the clinical activity is carried out at IRCCS Istituto Ortopedico Galeazzi, Ospedale San Raffaele Turro, Ospedale San Pietro – Policlinico San Marco (BG), or Columbus Clinic (MI)*

Feb 2021 - present **Quality control Committee of the Kidney Cancer Disease Unit**

San Raffaele Hospital– Via Olgettina 60 – 20132 Milan

Pathology Department (Chief: Prof. C. Doglioni)

2017 - present **Second-opinion consultation Uropathologist**

San Raffaele Hospital– Via Olgettina 60 – 20132 Milan

Pathology Department

Review of outside material of prostate, bladder, kidney and testis pathological samples, PD-L1, Trop2, and Nectin-4 IHC expression.

Dec 2012- Dec 2016 **Consultant Pathologist**

San Raffaele Hospital– Via Olgettina 60 – 20132 Milan

Pathology Department (Chief: Prof. C. Doglioni)

Grossing and processing of surgical specimens. Preparation of paraffin embedded tissue, as well as intraoperative frozen sections. Assessment of H&E-stained, and immunohistochemistry (IHC) specimens. Expertise in molecular pathology techniques

Aug 2012- Nov 2016 **Consultant Pathologist**

San Raffaele Hospital– Via Olgettina 60 – 20132 Milan

Pathology Department (Chief: Prof. C. Doglioni)

Grossing and processing of surgical specimens. Preparation of paraffin embedded tissue, as well as intraoperative frozen sections. Assessment of H&E-stained, and immunohistochemistry (IHC) specimens. Expertise in molecular pathology techniques.

Feb 2012- Jul 2016 **Consultant Pathologist**

San Raffaele Hospital– Via Olgettina 60 – 20132 Milan

Pathology Department (Chief: Prof. C. Doglioni)

Grossing and processing of surgical specimens. Preparation of paraffin embedded tissue, as well as intraoperative frozen sections. Assessment of H&E-stained, and immunohistochemistry (IHC) specimens. Expertise in molecular pathology techniques

- Feb 2011- Jan 2012 **Consultant Pathologist**
 San Raffaele Hospital– Via Olgettina 60 – 20132 Milan
 Pathology Department (Chief: Prof. C. Doglioni)
 Grossing and processing of surgical specimens. Preparation of paraffin embedded tissue, as well as intraoperative frozen sections. Assessment of H&E-stained, and immunohistochemistry (IHC) specimens. Expertise in molecular pathology techniques
- Mar 2011 – Aug 2011 **Consultant Pathologist**
 Istituto Nazionale dei Tumori IRCCS– Via Giacomo Venezian, 1, 20133 Milano MI
 Pathology Department
 Grossing and processing of surgical specimens. Preparation of paraffin embedded tissue, as well as intraoperative frozen sections. Assessment of H&E-stained, and immunohistochemistry (IHC) specimens. Expertise in molecular pathology techniques
- Apr 2005 - Jun 2010 **Technical Consultant**
 Tribunale Civile di Locri (R.C.) – Procura della Repubblica di Locri (R.C.)
- 10th May 2010 **Health Assistant**
 Comitato Giochi Paraolimpici, Regione Calabria
- Jul 2009 **Deputy General practitioner**
 Studio di Medicina Generale Dott.ssa Renne, Locri (R.C.)
- Oct 2005 - Jan 2006 **Medical Assistant**
 Casa di Cura Caminiti, Villa S. Giovanni (R.C.)
- Apr 2005, Aug 2005, Oct 2005 **Medical Assistant**
 Azienda Sanitaria ASL n°9, Locri (R.C.)
- Aug 2005 - Sep 2005 **Deputy General Practitioner**
 Studio di Medicina Generale Dott. De Angelis, Brancaleone (R.C.)

EDUCATION AND TRAINING

- Aug 2018 – Oct 2018** **Preceptorship in Uropathology**
Carnegie Ave, Cleveland, OH 44103, Stati Uniti
Pathology Department
Research activity in the field of prostate, bladder, kidney, and testicular pathology with particular focus on H&E samples; journal club participations; multidisciplinary discussion of clinical cases with Dr. J.K. MacKenney and Dr. C. Magigalluzzi)
- Oct 2005- Oct 2010** **Residency in Pathology**
Faculty of Medicine and Surgery - University of Messina - Policlinico Universitario "G. Martino "- Messina
50/50 cum laude (*with special mention*)
"Ruolo della Neutrophil Gelatinose-Associated Lipocalin (NGAL/Lcn2) nella Patologia Neoplastica: espressione immunoistochimica e valore prognostico nel carcinoma del colon-retto"
- Oct 1998 - Oct 2004** **Master's Degree in Medicine and Surgery**
University of Messina - Policlinico Universitario "G. Martino "- Messina
101/110
"Nevo Comedonico Oggi"
- July 1996** **High School Diploma**
Liceo Scientifico "F. La Cava" – Bovalino (R.C.)
58/60

PERSONAL SKILLS

- Languages** ITALIAN (mother tongue)
ENGLISH (advanced)
- Technical competences** Expert use of Microsoft Office Suite
Good practical knowledge of rotary microtome, preparation of histologic sections, and use of cryostat for preparation of frozen sections
Practical knowledge of staining (Hematoxylin and Eosin, Giemsa, Papanicolaou etc.)
- Driving Licence** Type B

MEMBERSHIP IN SCIENTIFIC SOCIETIES

2017 – present: SIURO
2015 – present: SIAPEC
2018 – present: GUPS
2022- present: ESP

OFFICIAL POSITION IN SCIENTIFIC SOCIETIES

2022 – 2025 SIURO - Steering Committee

RESEARCH PROJECTS

2012 – 2019 Analisi dell'espressione di microRna nella progressione del carcinoma prostatico - URI (Urological Research Institute - Prof. F. Montorsi)
2012 – 2016 Studio dell'espressione di geni rilevanti nella progressione dei Tumori Urologici - URI (Urological Research Institute - Prof. F. Montorsi)
2011 – 2012 Attivazione estro-progestinica e aggressività del carcinoma prostatico - URI (Urological Research Institute – Prof. F. Montorsi)
2011 Valutazione dell'espressione di microRNA nel carcinoma prostatico mirata all'identificazione di nuovi marcatori diagnostici e prognostici

PARTICIPATIONS IN MULTI-INSTITUTIONAL CLINICAL STUDIES

1. Co-investigator of the **B8011006 (CREST) study**: A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 Antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants With High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer. IRCCS San Raffaele Hospital, Milano.
2. Co-investigator of the **PEGASUS study**: An open-label, single-arm, Phase II study, evaluating safety and efficacy of INCB054828 (Pemigatinib) as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma who have received radical surgery.
3. Co-investigator of the **D933RC00001 (NIAGARA) study**: A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine + Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer

SCIENTIFIC PUBLICATIONS

ORIGINAL PAPERS (INTERNATIONAL PEER-REVIEW JOURNALS): 49

H-INDEX: 20

CITATIONS: 1577

(Source: Scopus, November 2022)

The list of international indexed publications are ordered according to the date of publication:

1: Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, Costa de Padua T, Crupi E, Colombo R, Colecchia M, **Lucianò R**, Nocera L, Moschini M, Briganti A, Montorsi F, Necchi A. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial. Clin Cancer Res. 2022 Oct 3;CCR-22-2158. doi: 10.1158/1078-0432.CCR-22-2158. Epub ahead of print. PMID: 36190522.

2: Cignoli D, Fallara G, Aleotti F, Larcher A, Rosiello G, Rowe I, Basile G, Colandrea G, Martini A, De Cobelli F, Brembilla G, **Lucianò R**, Colecchia M, Lena MS, Partelli S, Tamburrino D, Zamboni G, Rubini C, Falconi M, Montorsi F, Salonia A, Capitanio U. Pancreatic metastases after surgery for renal cell carcinoma: survival and pathways of progression. World J Urol. 2022 Oct;40(10):2481-2488. doi: 10.1007/s00345-022-04106-z. Epub 2022 Jul 29. PMID: 35904571.

3: De Marchi D, Tafuri A, Mantica G, Shakir A, Scarfò F, Passaretti G, Smelzo S, Proietti S, Rigatti L, **Luciano R**, Antonelli A, Pagliarulo V, Leonardi R, Giusti G, Gaboardi F. Ectopic adrenal tissue in the kidney: A systematic review. Arch Ital Urol Androl. 2021 Dec 21;93(4):481-488. doi: 10.4081/aiua.2021.4.481. PMID: 34933527.

4: **Lucianò R**, Tenace NP, Pederzoli F, Alfano M, Colecchia M, Montorsi F, Doglioni C, Salonia A. Leiomyoadenomatoid tumours of the epididymis: A new case report and review of the literature. Andrologia. 2022 Feb;54(1):e14280. doi: 10.1111/and.14280. Epub 2021 Oct 17. PMID: 34658055.

5: Rodriguez Pena MDC, Canete-Portillo S, Amin A, Aron M, Colombo P, Cox R, Baydar DE, Gallegos I, Khani F, Michalova K, **Lucianò R**, Miyamoto H, Osunkoya AO, Raspollini MR, Sánchez DF, Scarfo F, So JS, Zynger DL, Wei S, Netto GJ, MagiGalluzzi C. Testicular Germ-Cell Tumors with Spermatic Cord Involvement: A Retrospective International Multi-Institutional Experience. Mod Pathol. 2022 Feb;35(2):249-255. doi: 10.1038/s41379-021-00912-9. Epub 2021 Sep 9. PMID: 34504308.

6: Pellegrino F, Coghi A, Lavorgna G, Cazzaniga W, Guazzoni E, Locatelli I, Villa I, Bolamperti S, Finocchio N, Alfano M, **Lucianò R**, Briganti A, Montorsi F, Salonia A, Cavarretta I. A mechanistic insight into the anti-metastatic role of the prostate specific antigen. Transl Oncol. 2021 Nov;14(11):101211. doi: 10.1016/j.tranon.2021.101211. Epub 2021 Aug 26. PMID: 34455373; PMCID: PMC8403584.

7: Necchi A, Martini A, Raggi D, Cucchiara V, Colecchia M, **Lucianò R**, Villa L, Mazzone E, Basile G, Scuderi S, Pederzoli F, Bandini M, Barletta F, Larcher A, Capitanio U, Salonia A, Briganti A, Ross JS, Messina A, Montorsi

F. A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. *Urol Oncol*. 2022 Jan;40(1):10.e1-10.e6. doi: 10.1016/j.urolonc.2021.05.014. Epub 2021 Jun 17. PMID: 34147313.

8: Sorce G, Stabile A, **Lucianò R**, Motterle G, Scuderi S, Barletta F, Pellegrino F, Cucchiara V, Gandaglia G, Fossati N, De Cobelli F, Montorsi F, Jeffrey Karnes R, Guccini I, Briganti A. Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions. *BJU Int*. 2022 Feb;129(2):201-207. doi: 10.1111/bju.15498. Epub 2021 Jun 13. PMID: 34038039.

9: Trevisani F, Di Marco F, Capitanio U, Dell'Antonio G, Cinque A, Larcher A, **Lucianò R**, Bettiga A, Vago R, Briganti A, Salonia A, Montorsi F, Porrini E. Correction to: Renal histology across the stages of chronic kidney disease. *J Nephrol*. 2021 Jun;34(3):961. doi: 10.1007/s40620-021-01059-1. Erratum for: *J Nephrol*. 2021 Jun;34(3):699-707. PMID: 33983625.

10: Smelzo S, Mantica G, **Lucianò R**, Tenace NP, De Marchi D, Pini G, Passaretti G, Losa A, Gaboardi F. Prostate cancer testicular metastasis: Are they underestimated? Case report and analysis of the literature. *Urologia*. 2022 Nov;89(4):645-647. doi: 10.1177/03915603211009118. Epub 2021 Apr 8. PMID: 33832367.

11: Trevisani F, Di Marco F, Capitanio U, Dell'Antonio G, Cinque A, Larcher A, **Lucianò R**, Bettiga A, Vago R, Briganti A, Salonia A, Montorsi F, Porrini E. Renal histology across the stages of chronic kidney disease. *J Nephrol*. 2021 Jun;34(3):699-707. doi: 10.1007/s40620-020-00905-y. Epub 2021 Jan 4. Erratum in: *J Nephrol*. 2021 May 13;: PMID: 33394348.

12: Nini A, Muttin F, Cianflone F, Carenzi C, **Luciano R**, Catena M, Larcher A, Salvioni M, Cazzaniga W, Pederzoli F, Matloob R, Colombo R, Paganelli M, Salonia A, Briganti A, Doglioni C, Zangrillo A, DE Cobelli F, Rigatti P, Freschi M, Cornero G, Nicoletti R, Aldrighetti L, Montorsi F, Capitanio U, Bertini R. Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. *Minerva Urol Nephrol*. 2021 Dec;73(6):746-753. doi: 10.23736/S2724-6051.20.03844-8. Epub 2020 Nov 27. PMID: 33242949.

13: Costantini M, Amoreo CA, Torregrossa L, Alì G, Munari E, Jeronimo C, Henrique R, Petronilho S, Capitanio U, **Lucianò R**, Suardi N, Landi MT, Anceschi U, Brassetti A, Fazio VM, Gallucci M, Simone G, Sentinelli S, Poeta ML. Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication. *Cancers (Basel)*. 2020 Nov 12;12(11):3345. doi: 10.3390/cancers12113345. PMID: 33198197; PMCID: PMC7697829.

14: Zuppone S, Bresolin A, Spinelli AE, Fallara G, **Lucianò R**, Scarfò F, Benigni F, Di Muzio N, Fiorino C, Briganti A, Salonia A, Montorsi F, Vago R, Cozzarini C. Pre-clinical Research on Bladder Toxicity After Radiotherapy for Pelvic Cancers: State-of-the Art and Challenges. *Front Oncol*. 2020 Oct 22;10:527121. doi: 10.3389/fonc.2020.527121. PMID: 33194587; PMCID: PMC7642999.

- 15: Cimadamore A, Cheng L, Lopez-Beltran A, Mazzucchelli R, **Lucianò R**, Scarpelli M, Montorsi F, Montironi R. Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review. *Eur Urol Oncol*. 2021 Aug;4(4):558-569. doi: 10.1016/j.euo.2020.08.003. Epub 2020 Aug 31. PMID: 32883645.
- 16: Proietti S, Rodríguez-Socarrás ME, Eisner BH, **Lucianò R**, Basulto Martinez MJ, Yeow Y, Rapallo I, Saitta G, Scarfò F, Gaboardi F, Giusti G. Thulium:YAG vs Holmium:YAG Laser Effect on Upper Urinary Tract Soft Tissue: Evidence from an Ex Vivo Experimental Study. *J Endourol*. 2021 Apr;35(4):544-551. doi: 10.1089/end.2020.0222. Epub 2020 Sep 7. PMID: 32808543.
- 17: Capitanio U, Pepe G, Incerti E, Larcher A, Trevisani F, **Lucianò R**, Mapelli P, Bettinardi V, Monterisi C, Necchi A, Cascinu S, Bernardi R, Bertini R, Doglioni C, Gianolli L, Salonia A, Picchio M, Montorsi F. The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial. *Eur J Nucl Med Mol Imaging*. 2021 Feb;48(2):554-560. doi: 10.1007/s00259-020-04936-2. Epub 2020 Jul 8. PMID: 32638098.
- 18: Bandini M, Ross JS, Raggi D, Gallina A, Colecchia M, **Lucianò R**, Giannatempo P, Farè E, Pederzoli F, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Deho' F, Ali SM, Madison R, Chung JH, Salonia A, Briganti A, Montorsi F, Necchi A. Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. *J Natl Cancer Inst*. 2021 Jan 4;113(1):48-53. doi: 10.1093/jnci/djaa076. PMID: 32516377; PMCID: PMC7781448.
- 19: Necchi A, Raggi D, Giannatempo P, Marandino L, Farè E, Gallina A, Colecchia M, **Lucianò R**, Salonia A, Gandaglia G, Fossati N, Bandini M, Pederzoli F, Dittamore R, Liu Y, Davicioni E, Ross JS, de Jong JJ, Briganti A, Montorsi F, Gibb EA. Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. *Eur Urol Oncol*. 2021 Dec;4(6):1001-1005. doi: 10.1016/j.euo.2020.04.005. Epub 2020 May 14. PMID: 32417369.
- 20: Pederzoli F, Ferrarese R, Amato V, Locatelli I, Alchera E, **Lucianò R**, Nebuloni M, Briganti A, Gallina A, Colombo R, Necchi A, Clementi M, Montorsi F, Mancini N, Salonia A, Alfano M. Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients. *Eur Urol Oncol*. 2020 Dec;3(6):784-788. doi: 10.1016/j.euo.2020.04.002. Epub 2020 Apr 25. PMID: 32345542.
- 21: Necchi A, Raggi D, Gallina A, Ross JS, Farè E, Giannatempo P, Marandino L, Colecchia M, **Lucianò R**, Bianchi M, Colombo R, Salonia A, Gandaglia G, Fossati N, Bandini M, Pederzoli F, Capitanio U, Montorsi F, de Jong JJ, Dittamore R, Liu Y, Davicioni E, Boormans JL, Briganti A, Black PC, Gibb EA. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. *Eur Urol*. 2020 Jun;77(6):701-710. doi: 10.1016/j.eururo.2020.02.028. Epub 2020 Mar 9. PMID: 32165065.

22: Bandini M, Pederzoli F, Madison R, Briganti A, Ross JS, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Rosenberg JE, Bellmunt J, Pal SK, Galsky MD, **Lucianò R**, Gallina A, Salonia A, Montorsi F, Ali SM, Chung JH, Necchi A. Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi- institutional Study. Clin Genitourin Cancer. 2020 Oct;18(5):e543-e556. doi: 10.1016/j.clgc.2020.01.007. Epub 2020 Feb 8. PMID: 32144050; PMCID: PMC8491463.

23: Proietti S, Marchioni M, Eisner BH, **Lucianò R**, Saitta G, Rodríguez-Socarrás ME, D'Orta C, Bellinzoni P, Schips L, Gaboardi F, Giusti G. Conservative treatment of upper urinary tract carcinoma in patients with imperative indications. Minerva Urol Nephrol. 2021 Apr;73(2):245-252. doi: 10.23736/S2724-6051.20.03710-8. Epub 2020 Feb 19. PMID: 32083422.

24: Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Farè E, Colecchia M, Marandino L, Bianchi M, Gallina A, Colombo R, Fossati N, Gandaglia G, Capitanio U, Dehò F, Giannatempo P, **Lucianò R**, Salonia A, Madison R, Ali SM, Chung JH, Ross JS, Briganti A, Montorsi F, De Cobelli F, Messina A. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol. 2020 May;77(5):636-643. doi: 10.1016/j.eururo.2019.12.016. Epub 2019 Dec 25. PMID: 31882281.

25: Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, **Lucianò R**, Montironi R, Giannatempo P, Farè E, Pederzoli F, Bandini M, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Dehò F, Ali SM, Chung JH, Ross JS, Salonia A, Briganti A, Montorsi F. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle- invasive Bladder Carcinoma with Variant Histologies. Eur Urol. 2020 Apr;77(4):439-446. doi: 10.1016/j.eururo.2019.10.026. Epub 2019 Nov 8. PMID: 31708296.

26: Sorini C, Cosorich I, Lo Conte M, De Giorgi L, Facciotti F, Lucianò R, Rocchi M, Ferrarese R, Sanvito F, Canducci F, Falcone M. Loss of gut barrier integrity triggers activation of islet-reactive T cells and autoimmune diabetes. Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15140-15149. doi: 10.1073/pnas.1814558116. Epub 2019 Jun 10. PMID: 31182588; PMCID: PMC6660755.

27: Tom MC, Nguyen JK, **Lucianò R**, Mian OY, Stephans KL, Ciezki JP, Smile TD, Wei W, McKenney JK, Magi-Galluzzi C, Tendulkar RD. Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy. J Urol. 2019 Oct;202(4):710-716. doi: 10.1097/JU.0000000000000316. Epub 2019 Sep 6. PMID: 31059665.

28: Necchi A, Anichini A, Raggi D, Briganti A, Massa S, **Lucianò R**, Colecchia M, Giannatempo P, Mortarini R, Bianchi M, Farè E, Monopoli F, Colombo R, Gallina A, Salonia A, Messina A, Ali SM, Madison R, Ross JS, Chung JH, Salvioni R, Mariani L, Montorsi F. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open- Label, Single-Arm, Phase II Study. J Clin Oncol. 2018 Dec 1;36(34):3353-3360. doi: 10.1200/JCO.18.01148. Epub 2018 Oct 20. PMID: 30343614.

29: Canti V, Del Rosso S, Tonello M, **Lucianò R**, Hoxha A, Coletto LA, Vaglio Tessoro I, Rosa S, Manfredi AA, Castiglioni MT, Ruffatti A, Rovere-Querini P. Antiphosphatidylserine/prothrombin Antibodies in Antiphospholipid Syndrome with Intrauterine Growth Restriction and Preeclampsia. *J Rheumatol*. 2018 Aug;45(9):1263-1272. doi: 10.3899/jrheum.170751. Epub 2018 Jul 15. PMID: 30008452.

30: Fichera D, **Luciano R**, Nini A, Freschi M, Doglioni C, Bertini R, Montorsi F, Capitanio U. Clinical and pathological characteristics of a series of patients with newly diagnosed primary renal liposarcoma: natural history and effect on survival. *Arch Esp Urol*. 2018 Jul;71(6):555-558. English. PMID: 29991665.

31: Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros MB, Neeb A, **Lucianò R**, Bravi CA, Nava-Rodrigues D, Dolling D, Prayer-Galetti T, Ferreira A, Briganti A, Esposito A, Barry S, Yuan W, Sharp A, de Bono J, Alimonti A. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. *Nature*. 2018 Jul;559(7714):363-369. doi: 10.1038/s41586-018-0266-0. Epub 2018 Jun 27. PMID: 29950727; PMCID: PMC6461206.

32: Cortesi F, Delfanti G, Grilli A, Calcinotto A, Gorini F, Pucci F, **Lucianò R**, Grioni M, Recchia A, Benigni F, Briganti A, Salonia A, De Palma M, Biciato S, Doglioni C, Bellone M, Casorati G, Dellabona P. Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. *Cell Rep*. 2018 Mar 13;22(11):3006-3020. doi: 10.1016/j.celrep.2018.02.058. PMID: 29539427.

33: Nini A, Capitanio U, Larcher A, Dell'Oglio P, Dehò F, Suardi N, Muttin F, Carenzi C, Freschi M, **Lucianò R**, La Croce G, Briganti A, Colombo R, Salonia A, Castiglioni A, Rigatti P, Montorsi F, Bertini R. Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium. *Eur Urol*. 2018 May;73(5):793-799. doi: 10.1016/j.eururo.2017.08.019. Epub 2017 Sep 13. PMID: 28917595.

34: Petitprez F, Fossati N, Vano Y, Freschi M, Becht E, **Lucianò R**, Calderaro J, Guédet T, Lacroix L, Rancoita PMV, Montorsi F, Fridman WH, Sautès-Fridman C, Briganti A, Doglioni C, Bellone M. PD-L1 Expression and CD8 T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. *Eur Urol Focus*. 2019 Mar;5(2):192-196. doi: 10.1016/j.euf.2017.05.013. Epub 2017 Jun 21. PMID: 28753812.

35: Colombo R, Hurle R, Moschini M, Freschi M, Colombo P, Colecchia M, Ferrari L, **Lucianò R**, Conti G, Magnani T, Capogrosso P, Conti A, Pasini L, Burgio G, Guazzoni G, Patriarca C. Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High- Grade Bladder Cancer. *Eur Urol Focus*. 2018 Jan;4(1):87-93. doi: 10.1016/j.euf.2016.06.004. Epub 2016 Jun 15. PMID: 28753746.

36: Cazzaniga W, Nebuloni M, Longhi E, Locatelli I, Allevi R, **Lucianò R**, Senatore G, Ventimiglia E, Cucchiara V, Genovese L, Montorsi F, Alfano M, Salonia A, Cavarretta I. Human Prostate Tissue-derived Extracellular Matrix as a Model of Prostate Microenvironment. *Eur Urol Focus*. 2016 Oct;2(4):400-408. doi:

10.1016/j.euf.2016.02.016. Epub 2016 Mar 10. PMID: 28723472.

37: Cavarretta I, Ferrarese R, Cazzaniga W, Saita D, **Lucianò R**, Ceresola ER, Locatelli I, Visconti L, Lavorgna G, Briganti A, Nebuloni M, Doglioni C, Clementi M, Montorsi F, Canducci F, Salonia A. The Microbiome of the Prostate Tumor Microenvironment. *Eur Urol*. 2017 Oct;72(4):625-631. doi: 10.1016/j.eururo.2017.03.029. Epub 2017 Apr 20. PMID: 28434677.

38: Bettiga A, Aureli M, Colciago G, Murdica V, Moschini M, **Lucianò R**, Canals D, Hannun Y, Hedlund P, Lavorgna G, Colombo R, Bassi R, Samarani M, Montorsi F, Salonia A, Benigni F. Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism. *Sci Rep*. 2017 Feb 13;7:42157. doi: 10.1038/srep42157. PMID: 28191815; PMCID: PMC5304189.

39: Moschini M, Dell'Oglio P, **Luciano' R**, Gandaglia G, Soria F, Mattei A, Klatte T, Damiano R, Shariat SF, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. *Urol Oncol*. 2017 Jun;35(6):335-341. doi: 10.1016/j.urolonc.2016.12.006. Epub 2017 Jan 10. PMID: 28087131.

40: Moschini M, Shariat SF, **Lucianò R**, D'Andrea D, Foerster B, Abufaraj M, Bandini M, Dell'Oglio P, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. *Clin Genitourin Cancer*. 2017 Aug;15(4):e603-e607. doi: 10.1016/j.clgc.2016.12.006. Epub 2016 Dec 14. PMID: 28040422.

41: Alfano M, Nebuloni M, Allevi R, Zerbi P, Longhi E, **Lucianò R**, Locatelli I, Pecoraro A, Indrieri M, Speziali C, Doglioni C, Milani P, Montorsi F, Salonia A. Linearized texture of three-dimensional extracellular matrix is mandatory for bladder cancer cell invasion. *Sci Rep*. 2016 Oct 25;6:36128. doi: 10.1038/srep36128. PMID: 27779205; PMCID: PMC5078769.

42: Patriarca C, Hurle R, Moschini M, Freschi M, Colombo P, Colecchia M, Ferrari L, Guazzoni G, Conti A, Conti G, **Lucianò R**, Magnani T, Colombo R. Usefulness of pT1 substaging in papillary urothelial bladder carcinoma. *Diagn Pathol*. 2016 Jan 20;11:6. doi: 10.1186/s13000-016-0466-6. PMID: 26791567; PMCID: PMC4721190.

43: Suardi N, Dell'Oglio P, Gallina A, Gandaglia G, Buffi N, Moschini M, Fossati N, Lughezzani G, Karakiewicz PI, Freschi M, **Lucianò R**, Shariat SF, Guazzoni G, Gaboardi F, Montorsi F, Briganti A. Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. *Urol Oncol*. 2016 Feb;34(2):57.e1-7. doi: 10.1016/j.urolonc.2015.08.019. Epub 2015 Oct 1. PMID: 26427694.

44: Abrate A, Buono R, Canu T, Esposito A, Del Maschio A, **Lucianò R**, Bettiga A, Colciago G, Guazzoni G, Benigni F, Hedlund P, Altaner C, Montorsi F, Cavarretta IT. Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression. *Eur J Cancer*. 2014 Sep;50(14):2478-88. doi: 10.1016/j.ejca.2014.06.014. Epub 2014 Jul 21. PMID: 25060826.

- 45: Caruso R, Palmeri R, Racchiusa S, Bonanno A, **Lucianò R**, Scardigno M, Branca G, Fedele F. Pleomorphic ductal carcinoma of the male breast: report of a rare case and review of literature. *Anticancer Res.* 2011 Sep;31(9):3069-71. PMID: 21868561.
- 46: Caruso RA, Parisi A, Quattrocchi E, Scardigno M, Branca G, Parisi C, Lucianò R, Paparo D, Fedele F. Ultrastructural descriptions of heterotypic aggregation between eosinophils and tumor cells in human gastric carcinomas. *Ultrastruct Pathol.* 2011 Aug;35(4):145-9. doi: 10.3109/01913123.2011.578233. Epub 2011 Jun 9. PMID: 21657821.
- 47: Caruso R, Fedele F, **Lucianò R**, Branca G, Parisi C, Paparo D, Parisi A. Mitotic catastrophe in malignant epithelial tumors: the pathologist's viewpoint. *Ultrastruct Pathol.* 2011 Apr;35(2):66-71. doi: 10.3109/01913123.2010.543753. PMID: 21299346.
- 48: Barresi V, **Lucianò R**, Vitarelli E, Labate A, Tuccari G, Barresi G. Neutrophil gelatinase-associated lipocalin immunoexpression in colorectal carcinoma: A stage-specific prognostic factor? *Oncol Lett.* 2010 Nov;1(6):1089-1096. doi: 10.3892/ol.2010.191. Epub 2010 Sep 23. PMID: 22870118; PMCID: PMC3412518.
- 49: Caruso RA, Fedele F, Crisafulli C, Paparo D, Parisi A, **Lucianò R**, Cavallari V. Abnormal nuclear structures (micronuclei, nuclear blebs, strings, and pockets) in a case of anaplastic giant cell carcinoma of the thyroid: an immunohistochemical and ultrastructural study. *Ultrastruct Pathol.* 2011 Feb;35(1):14-8. doi: 10.3109/01913123.2010.517899. Epub 2010 Oct 7. PMID: 20925599.

LIST OF ORAL COMMUNICATIONS AND POSTERS

1. Bravi CA, Gandaglia G, Fossati N, Lucianò R, Zaffuto E, Scattoni V, Gallina A, Bertini R, Freschi F, Shariat SF, Mirone V, Karakiewicz P, Montironi R, Doglioni C, Montorsi F, Briganti A PREVALENCE AND PROGNOSTIC IMPACT OF PROSTATE CANCER HISTOLOGICAL VARIANTS AT RADICAL PROSTATECTOMY: A LONG-TERM, SINGLE CENTER ANALYSIS The Journal of Urology – Aprile 2018 DOI 10.1016/j.juro.2018.02.1101
2. Mazzone E, Gandaglia G, Fossati N, Dell'Oglio P, Suardi N, Zaffuto E, Freschi M, Lucianò R, Larcher A, Mirone V, Colombo R, Gaboardi F, Montorsi F, Briganti A THE IMPORTANCE OF THE SIZE OF NODAL METASTASES IN PREDICTING RECURRENCE OF NODE POSITIVE PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION: IMPLICATIONS FOR POST-OPERATIVE TREATMENT TAILORING The Journal of Urology – Aprile 2018 DOI 10.1016/j.juro.2018.02.370
3. Gandaglia G, Scuderi S, Fossati N, Brembilla G, Dell'Oglio P, Abdollah F, Freschi M, Grillo L, Lucianò R, Bandini M, Nini A, Montironi R, Mirone V, Esposito A, De Cobelli F, Gaboardi F, Montorsi F, Briganti A WHERE DO WE MISS EXTRACAPSULAR EXTENSION AT MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF THE PROSTATE? The Journal of Urology – Aprile 2018 DOI 10.1016/j.juro.2018.02.1688
4. Nini A, Muttin F, Cianflone F, Carenzi C, Lucianò R, Catena M, Lapenna E, Larcher A, Pederzoli F, Matloob R, La Croce G, Colombo R, Paganelli M, Montorsi F, Doglioni C, Zangrillo A, Alfieri O, Rigatti P, Capitanio U, Freschi M, Cornero G, Castiglioni A, Aldrighetti L, Bertini R COMPARISON BETWEEN LIVER DEROTATION WITH PRINGLE MANOEUVRE AND CARDIOPULMONARY BYPASS WITH DEEP-HYPOTHERMIC CARDIAC ARREST FOR KIDNEY CANCER WITH MAYO III TUMOR THROMBUS: INTRA-, PERI- AND POSTOPERATIVE OUTCOMES The Journal of Urology – Aprile 2018 DOI 10.1016/j.juro.2018.02.1205
5. Nini A, Cianflone F, Lucianò R, Larcher A, Carenzi C, Cazzaniga W, Matloob R, Montorsi F, Doglioni C, Gianolli L, Rigatti P, De Cobelli F, Del Maschio A, Gandaglia G, Briganti A, Salonia A, Picchio M, Freschi M, Nicoletti R, Capitanio U, Bertini R THE ROLE OF HISTOLOGIC SUBTYPES IN FOLLOW-UP SCHEME OF POSTSURGICAL KIDNEY CANCER PATIENTS The Journal of Urology – Aprile 2018 DOI 10.1016/j.juro.2018.02.1150 Ventimiglia E, Coggiato G, Ottria R, Lucianò R, Ciuffreda P, Salonia A, Montorsi F, Benigni F, Hedlund P, Cavarretta I THE EXPRESSION OF THE ATYPICAL CANNABINOID RECEPTOR GPR55 DECREASES IN HUMAN PROSTATE CANCER SPECIMENS San Raffaele Scientific Retreat – Edizione 2013
6. 694 Prediction of long-term cancer recurrence after radical prostatectomy in patients with lymph node invasion: Results of conditional survival analysis Abdollah, F. et al. European Urology Supplements, Volume 12, Issue 1, e694
7. The effect of anatomical location of retroperitoneal lymph node metastases on cancer specific survival in patients with clear cell renal cell carcinoma Nini, A. et al. European Urology Supplements, Volume 16, Issue 3, e1348 - e1349
8. 267 Long term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: Results of a single institution series with a minimum follow-up of 5 years Di Trapani, E. et al. European Urology Supplements, Volume 13, Issue 1, e267
9. 187 A competing risks analysis of long term survival on node positive prostate cancer patients treated with radical prostatectomy Abdollah, F. et al. European Urology Supplements, Volume 12, Issue 1, e187

10. Defining clinically meaningful positive surgical margins in patients undergoing radical prostatectomy for localized prostate cancer: A stage-by-stage analysis on the risk of clinical recurrence Gandaglia, G. et al. *European Urology Supplements*, Volume 17, Issue 2, e572
11. Where do we miss extracapsular extension at multiparametric magnetic resonance imaging of the prostate? A site-per-site analysis in a single center, radical prostatectomy series Gandaglia, G. et al. *European Urology Supplements*, Volume 17, Issue 8, 351
12. Prevalence and prognostic impact of prostate cancer histological variants at radical prostatectomy: A long-term, single center analysis Bravi, C.A. et al. *European Urology Supplements*, Volume 17, Issue 2, e1859
13. The role of histologic subtypes in follow-up scheme of postsurgical kidney cancer patients Nini, A. et al. *European Urology Supplements*, Volume 17, Issue 2, e435
14. The gender-specific urinary and bladder tissue microbiome in therapy-naïve bladder cancer patients Pederzoli, F. et al. *European Urology Supplements*, Volume 18, Issue 11, e3603
15. 735 What is the prognostic impact of nodal tumour burden in patients with a single positive node at final pathology? Nini, A. et al. *European Urology Supplements*, Volume 15, Issue 3, e735
16. The importance of the size of nodal metastases in predicting recurrence of node positive prostate cancer patients treated with radical prostatectomy and extended pelvic lymph node dissection: Implications for post-operative treatment tailoring Mazzone, E. et al. *European Urology Supplements*, Volume 17, Issue 2, e1500
17. 799 Thirty years of radical prostatectomies at a single European tertiary care referral center Dell'Oglio, P. et al. *European Urology Supplements*, Volume 14, Issue 2, e799
18. The importance of the size of nodal metastases in predicting recurrence of node positive prostate cancer patients treated with radical prostatectomy and extended pelvic lymph node dissection: Implications for post-operative treatment tailoring Mazzone, E. et al. *European Urology Supplements*, Volume 17, Issue 8, 274 - 275
19. Defining clinically meaningful positive surgical margins in patients undergoing radical prostatectomy for localized prostate cancer: A stage-by-stage analysis on the risk of clinical recurrence Martini, A. et al. *European Urology Supplements*, Volume 17, Issue 8, 307
20. Incongruence between turb and radical cystectomy findings in terms of histological variant identification: analysis of all potential clinical risk factors Gallina, A. et al. *European Urology Open Science*, Volume 20, S168
21. Incongruence between TURB and radical cystectomy findings in terms of histological variant identification: Analysis of all potential clinical risk factors Bandini, M. et al. *European Urology Open Science*, Volume 19, e1436
22. Impact of histological variants in node positive patients treated with radical cystectomy for bladder cancer Bandini, M. et al. *European Urology Open Science*, Volume 20, S167
23. Impact of histological variants in node positive patients treated with radical cystectomy for bladder cancer Bandini, M. et al. *European Urology Open Science*, Volume 19, e1526
24. The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial (NCT03955393) Capitanio, U. et al. *European Urology Open Science*, Volume 20, S130

25. Which positive surgical margins features impact on the risk of prostate cancer specific mortality? A disease-tailored, competing-risk, long-term analysis Scuderi, S. et al. European Urology Supplements, Volume 18, Issue 9, e3266 - e3267
26. Impact of molecular subtyping and immune infiltration on response and outcome following neoadjuvant pembrolizumab (pembro), versus neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer Necchi, A. et al. European Urology Open Science, Volume 19, e192 - e193

PARTICIPATIONS IN SEMINARS OR LECTURES

- “Corso di Patologia Digestiva” (National School of Surgical Pathology) – Prof. Roberto Fiocca – Genova, 7/9 May 2008
- “La Riproducibilità della Caratterizzazione Biologica del Cancro alla Mammella” - Prof. Viale – Milano, 17 April 2010
- “I mercoledì di Urologia al San Raffaele” - Prof. Claudio Doglioni - Dott. Massimo Freschi – Milano, 21 April 2010
- “I Tumori delle Parti Molli: un approccio diagnostico integrato” - Prof. Angelo Paolo dei Tos – Treviso, 12/14 May 2010
- “Urologia: l’obiettivo sulle questioni critiche per la clinica” – Dott. Carlo Patriarca - Como, 4 November 2013
- “Abortività spontanea nel primo trimestre gestazionale” - Accademia del Saper Fare -Genova, 20/21 November 2014
- “Milan Urology course. Morphological and molecular backgrounds for personalized therapies in Genitourinary Cancers” – Milano, 27/28 April 2015
- “I Sabati dell’urologia: aggiornamenti in urologia” – Milano – 12 December 2015
- “Hot Topics in Urology”- Dott.F.Crivelli – Sirone, 9 April 2016
- “Around the Bladder” – Ospedale Niguarda, Milano, 16/17 November 2017
- “Biopsia prostatica e RM multiparametrica: un evento congiunto” – SIRM-SIU – Milano, 5 December 2017
- “Milan Urology course. Kidney tutorial course – the challenging era of Immunotherapy” – Milano, 5-6 March 2018

ATTENDED CONFERENCES

- “Convegno Annuale A.I.D.N.I.D.” – Associazione Italiana Diagnostica non Invasiva in Dermatologia – Palermo, 24 June 2005
- “5th Conference on Integrated Therapies in Oncology State of the Art and Future Challenges” – Ospedale Policlinico “G.Martino” – Messina, 8/10 July 2008
- Congresso SIAPEC-IAP – Bari, 25/27 September 2008
- “IX Congresso Nazionale G.I.U.P. - Hot topics in Urological Pathology”.- Gruppo Italiano di Urologia Torino, 8 July 2011
- “28th EAU Conference” – Milano, 15-19 March 2013
- Congresso SIAPEC-IAP – Milano, 23-25 September 2015

SCIENTIFIC PRESENTATIONS AND LECTURES

- “Multidisciplinary Approach to Ob/Gyn Diseases: Obstetrics” Ospedale San Raffaele, March 2013
- “Gravidanza a termine, induzione del travaglio: buona pratica e ostacoli da superare” Ospedale Cà Granda

Niguarda, November 2015

- "Imaging RM del Carcinoma della Prostata" Ospedale San Raffaele, 9/10 November 2017
- "Surgery in the 3rd millennium: the future is female" Ospedale San Raffaele Turro, 12/13th April 2018
- Lecture on "Gestational Pathology" for medical students on 7th May 2019
- Lecture on superficial and muscle-infiltrating bladder cancer lesions – Autumn School, Naples, 7th November 2019
- Microscopy Practicals for Medical Students 2019
- "Carcinoma vescicale – dal NMIBC al trattamento del paziente metastatico" – Webinar, 20 November 2020
- Lecture on "Gestational Pathology" for medical students on 2020
- SIURO Lecture "Carcinoma prostatico ad alto rischio: ogni trattamento ha un suo tempo" – Webinar, 5 October 2020
- Microscopy Practicals for Medical Students 2020
- Lecture on "Gestational Pathology" for medical students on 2021
- Lecture on testicular cancer for urology residents December 2021
- SIURO Lecture "Back to school neoplasie vescicali" 2021
- Lecture for Pathology residents "Lezioni di campionamento urogenitale – Prostata e Rene" 18th february 2021
- SIAPEC Invited Lecture "Clinical Case Discussion" 25th November 2021
- Microscopy Practicals for Medical Students 2021

MODERATIONS AT NATIONAL AND INTERNATIONAL MEETINGS

- SLOG 2015: Lecture on "Placental Senescence"
- SIURO Lecture "L'importanza del referto anatomico-patologico " 2nd December 2021

Milano, Novembre 2022

In fede

Dott.ssa Roberta Lucianò